Clinical trials: MOG-IgG Associated Disease
Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders
Evaluation of Two Cell-based Assays for Diagnosing MOG-IgG Associated Disorders
Anti-myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD) is a rare inflammatory autoimmune disease. In addition, since the international MOGAD group proposed live-cell based assays for MOGAD diagnosis in 2023…
- Trial name
- NCT06617962
- Testing
- CBA method of live cells and fixed cells
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Trial name
- NCT07526493
- Testing
- Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Tongji Hospital
Central Nervous System Inflammation, MOG-IgG Associated Disease
Azathioprine in MOGAD
MOG-IgG associated disease (MOGAD) is a rare inflammatory disease of the central nervous system recently described. Initially reported as monophasic, data from incident cohorts suggests that around 50% of adult patients with…
- Trial name
- MOGwAI (NCT05349006)
- Testing
- Azathioprine
- Where
- 17 sites in France
- Volunteers
- 126 people
- Sponsor
- Hospices Civils de Lyon
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD)
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory neurological autoimmune diseases.
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD), Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD), Myasthenia Gravis
- Trial name
- NCT06869278
- Testing
- LCAR-AIO T cells
- Where
- 3 sites in China
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology